Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
Make a selection below to explore our full database of 21 results matching: "Enoxaparin"
ACE Reports
(21 Reports)
ACE Reports
Originals
(0 Articles)
Originals
Podcasts
(0 Videos)
Podcasts
Our AI driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Spine
Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study.
Eur Spine J. 2025 01-May;():. 10.1007/s00586-025-08747-7
Rivaroxaban versus enoxaparin as thromboprophylaxis in degenerative spine surgery: a randomized blinded non-inferiority study.
Eur Spine J. 2025 01-May;():. 10.1007/s00586-025-08747-7
Arthroplasty
Aspirin or enoxaparin for VTE prophylaxis after primary partial, total or revision hip or knee arthroplasty: A secondary analysis from the CRISTAL cluster randomized trial.
PLoS One. 2024 01-Apr;():. 10.1371/journal.pone.0298152
Aspirin or enoxaparin for VTE prophylaxis after primary partial, total or revision hip or knee arthroplasty: A secondary analysis from the CRISTAL cluster randomized trial.
PLoS One. 2024 01-Apr;():. 10.1371/journal.pone.0298152
Arthroplasty
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial
JAMA. 2022 Aug 23;328(8):719-727. doi: 10.1001/jama.2022.13416.. 2022 01-Aug;():. 10.1001/jama.2022.13416
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial
JAMA. 2022 Aug 23;328(8):719-727. doi: 10.1001/jama.2022.13416.. 2022 01-Aug;():. 10.1001/jama.2022.13416
Arthroplasty
Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis
Orthop Traumatol Surg Res. 2021 01-Feb;():. 10.1016/j.otsr.2020.04.002
Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis
This report has been verified by one or more authors of the original publication.
Orthop Traumatol Surg Res. 2021 01-Feb;():. 10.1016/j.otsr.2020.04.002
General Orthopaedics
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery
N Engl J Med. 2020 01-May;():. 10.1056/NEJMoa1913808
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery
N Engl J Med. 2020 01-May;():. 10.1056/NEJMoa1913808
Arthroplasty
Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
Thromb J. 2015 Aug 12;13:27
Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V
This report has been verified by one or more authors of the original publication.
Thromb J. 2015 Aug 12;13:27
Arthroplasty
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial
Thromb Res. 2014 Dec;134(6):1198-204
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial
This report has been verified by one or more authors of the original publication.
Thromb Res. 2014 Dec;134(6):1198-204
Arthroplasty
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin
J Bone Joint Surg Am. 2001 Jun;83-A(6):900-6
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin
J Bone Joint Surg Am. 2001 Jun;83-A(6):900-6
Arthroplasty
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group
J Bone Joint Surg Am. 2001 Mar;83-A(3):336-45
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group
J Bone Joint Surg Am. 2001 Mar;83-A(3):336-45
Arthroplasty
Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention
Arch Orthop Trauma Surg. 2014 May;134(5):679-83. doi: 10.1007/s00402-014-1939-2. Epub 2014 Feb 18
Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention
Arch Orthop Trauma Surg. 2014 May;134(5):679-83. doi: 10.1007/s00402-014-1939-2. Epub 2014 Feb 18
Arthroplasty
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)
Thromb Haemost. 2014 Jan 29;111(2):213-25. doi: 10.1160/TH13-04-0296.
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)
This report has been verified by one or more authors of the original publication.
Thromb Haemost. 2014 Jan 29;111(2):213-25. doi: 10.1160/TH13-04-0296.
Arthroplasty
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials
Thromb Haemost. 2011 Feb;105(2):245-53
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials
Thromb Haemost. 2011 Feb;105(2):245-53
Arthroplasty
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial
Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial
This report has been verified by one or more authors of the original publication.
Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12
Arthroplasty
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons
This report has been verified by one or more authors of the original publication.
BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675
Arthroplasty
Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin
Knee. 2006 Mar;13(2):118-21. Epub 2006 Jan 4
Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin
Knee. 2006 Mar;13(2):118-21. Epub 2006 Jan 4
Arthroplasty
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Lancet. 2007 Sep 15;370(9591):949-56
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Lancet. 2007 Sep 15;370(9591):949-56
General Orthopaedics
Extended-Duration Thromboprophylaxis With Enoxaparin After Arthroscopic Surgery of the Anterior Cruciate Ligament: A Prospective, Randomized, Placebo-Controlled Study
Arthroscopy. 2007 Jul;23(7):696-702
Extended-Duration Thromboprophylaxis With Enoxaparin After Arthroscopic Surgery of the Anterior Cruciate Ligament: A Prospective, Randomized, Placebo-Controlled Study
Arthroscopy. 2007 Jul;23(7):696-702
Arthroplasty
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
This report has been verified by one or more authors of the original publication.
Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4
Arthroplasty
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
J Arthroplasty. 2009 Jan;24(1):1-9. Epub 2008 Apr 14
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
J Arthroplasty. 2009 Jan;24(1):1-9. Epub 2008 Apr 14
Arthroplasty
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24
Showing 1-20 of 21 results
1
2